The influence of the menstrual cycle, normal pregnancy and pre-eclampsia on platelet activation

Thrombosis and Haemostasis

Volumn 103, Issue 2, 2010, Pages 372-378

  Robb, Amy O ^a   Din, Jehangir N ^b   Mills, Nicholas L ^b   Smith, Imogen B J ^a   Blomberg, Anders ^c   Zikry, Mariam N L ^a   Raftis, Jennifer B ^b   Newby, David E ^b   Denison, Fiona C ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c UMEÅ UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Platelet activation; Platelet monocyte aggregates; Pre eclampsia; Pregnancy

Indexed keywords

BIOLOGICAL MARKER; CD40 LIGAND; PADGEM PROTEIN; PLASMA PROTEIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GESTATION PERIOD; HUMAN; IN VIVO STUDY; MENSTRUAL CYCLE; MONOCYTE; NULLIPARA; PREECLAMPSIA; PREGNANCY; PRIMIGRAVIDA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PUERPERIUM; THIRD TRIMESTER PREGNANCY; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGLUTINATION;

ADULT; BIOLOGICAL MARKERS; FEMALE; GESTATIONAL AGE; GRAVIDITY; HUMANS; LONGITUDINAL STUDIES; MENSTRUAL CYCLE; MIDDLE AGED; PLATELET ACTIVATION; POSTPARTUM PERIOD; PRE-ECLAMPSIA; PREGNANCY; YOUNG ADULT;

EID: 75749127467     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH08-12-0780     Document Type: Article

References (43)

1. Hellgren M. Hemostasis during normal pregnancy and puerperium. Semin Thromb Hemost 2003; 29: 125-130.
2. Gilabert J, Estelles A, Grancha S, et al. Fibrinolytic system and reproductive process with special reference to fibrinolytic failure in pre-eclampsia. Hum Reprod 1995; 10 (Suppl 2): 121-131.
3. James AH, Jamison MG, Biswas MS, et al. Acute myocardial infarction in pregnancy: a United States population-based study. Circulation 2006; 113: 1564-1571.
4. Mukamal KJ, Muller JE, Maclure M, et al. Variation in the risk of onset of acute myocardial infarction during the menstrual cycle. Am J Cardiol 2002; 90: 49-51.
5. Sarma J, Laan CA, Alam S, et al. Increased platelet binding to circulating monocytes in acute coronary syndromes. Circulation 2002; 105: 2166-2171.
6. Jungi TW, Spycher MO, Nydegger UE, et al. Platelet-leukocyte interaction: selective binding of thrombin-stimulated platelets to human monocytes, polymorphonuclear leukocytes, and related cell lines. Blood 1986; 67: 629-636.
7. Kageyama K, Nakajima Y, Shibasaki M, et al. Increased platelet, leukocyte, and endothelial cell activity are associated with increased coagulability in patients after total knee arthroplasty. J Thromb Haemost 2007; 5: 738-745.
8. Konijnenberg A, Stokkers EW, van der Post JA, et al. Extensive platelet activation in preeclampsia compared with normal pregnancy: enhanced expression of cell adhesion molecules. Am J Obstet Gynecol 1997; 176: 461-469.
9. Norris LA, Gleeson N, Sheppard BL, et al. Whole blood platelet aggregation in moderate and severe pre-eclampsia. Br J Obstet Gynaecol 1993; 100: 684-688.
10. Yamazaki H, Motomiya T, Kikutani N, et al. Platelet aggregation during menstrual cycle and pregnancy. Thromb Res 1979; 14: 333-340.
11. Zahavi J, Dreyfuss F, Kalef M, et al. Adenosine diphosphate-induced platelet aggregation in healthy women with and without a combined and sequential contraceptive pill. Am J Obstet Gynecol 1973; 117: 107-113.
12. Michelson AD, Barnard MR, Krueger LA, et al. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation 2001; 104: 1533-1537.
13. Brown MA, Lindheimer MD, de Swiet M, et al. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy 2001; 20: IX-XIV.
14. Harding SA, Din JN, Sarma J, et al. Flow cytometric analysis of circulating platelet-monocyte aggregates in whole blood: methodological considerations. Thromb Haemost 2007; 98: 451-456.
15. Egbor M, Ansari T, Morris N, et al. Morphometric placental villous and vascular abnormalities in early- and late-onset pre-eclampsia with and without fetal growth restriction. Br J Obstet Gynaecol 2006; 113: 580-589.
16. Rosin C, Brunner M, Lehr S, et al. The formation of platelet-leukocyte aggregates varies during the menstrual cycle. Platelets 2006; 17: 61-66.
17. Simpson EL, Lawrenson RA, Nightingale AL, et al. Venous thromboembolism in pregnancy and the puerperium: incidence and additional risk factors from a London perinatal database. Br J Obstet Gynaecol 2001; 108: 56-60.
18. Gerbasi FR, Bottoms S, Farag A, et al. Increased intravascular coagulation associated with pregnancy. Obstet Gynecol 1990; 75: 385-389.
19. Janes SL, Goodall AH. Flow cytometric detection of circulating activated platelets and platelet hyper-responsiveness in pre-eclampsia and pregnancy. Clin Sci (Lond) 1994; 86: 731-739.
20. Gatti L, Tenconi PM, Guarneri D, et al. Hemostatic parameters and platelet activation by flow-cytometry in normal pregnancy: a longitudinal study. Int J Clin Lab Res 1994; 24: 217-219.
21. Romero R, Snyder E, Scott D, et al. Beta-thromboglobulin during normal pregnancy, labor, and puerperium. Am J Perinatol 1988; 5: 109-112.
22. Star J, Rosene K, Ferland J, et al. Flow cytometric analysis of platelet activation throughout normal gestation. Obstet Gynecol 1997; 90: 562-568.
23. Holthe MR, Lyberg T, Staff AC, et al. Leukocyte-platelet interaction in pregnancies complicated with preeclampsia. Platelets 2005; 16: 91-97.
24. Markham SM, Dubin NH, Rock JA. The effect of the menstrual cycle and of decompression stress on arachidonic acid-induced platelet aggregation and on intrinsic platelet thromboxane production in women compared with men. Am J Obstet Gynecol 1991; 165: 1821-1829.
25. Faraday N, Goldschmidt-Clermont PJ, Bray PF. Gender differences in platelet GPIIb-IIIa activation. Thromb Haemost 1997; 77: 748-754.
26. Heilmann L, Rath W, Pollow K. Hemostatic abnormalities in patients with severe preeclampsia. Clin Appl Thromb Hemost 2007; 13: 285-291.
27. Karalis I, Nadar SK, Al Yemeni E, et al. Platelet activation in pregnancy-induced hypertension. Thromb Res 2005; 116: 377-383.
28. Borzychowski AM, Sargent IL, Redman CW. Inflammation and pre-eclampsia. Semin Fetal Neonatal Med 2006; 11: 309-316.
29. Larsen LF, Andersen HR, Hansen AB, et al. Variation in risk indicators of cardiovascular disease during the menstrual cycle: an investigation of within-subject variations in glutathione peroxidase, haemostatic variables, lipids and lipoproteins in healthy young women. Scand J Clin Lab Invest 1996; 56: 241-249.
30. Bagamery K, Landau R, Kvell K, et al. Different platelet activation levels in non-pregnant, normotensive pregnant, pregnancy-induced hypertensive and pre-eclamptic women. A pilot study of flow cytometric analysis. Eur J Obstet Gynecol Reprod Biol 2005; 121: 117-118.
31. Harlow FH, Brown MA, Brighton TA, et al. Platelet activation in the hypertensive disorders of pregnancy. Am J Obstet Gynecol 2002; 187: 688-695.
32. Acar K, Sucak A, Beyazit Y, et al. Lack of platelet activation reflected by circulating soluble glycoprotein V in pre-eclampsia. J Int Med Res 2007; 35: 704-708.
33. Lok CA, Nieuwland R, Sturk A, et al. Microparticle-associated P-selectin reflects platelet activation in preeclampsia. Platelets 2007; 18: 68-72.
34. Holthe MR, Staff AC, Berge LN, et al. Different levels of platelet activation in pre-eclamptic, normotensive pregnant, and nonpregnant women. Am J Obstet Gynecol 2004; 190: 1128-1134.
35. Felfernig-Boehm D, Salat A, Vogl SE, et al. Early detection of preeclampsia by determination of platelet aggregability. Thromb Res 2000; 98: 139-146.
36. Oron G, Ben-Haroush A, Hod M, et al. Serum-soluble CD40 ligand in normal pregnancy and in preeclampsia. Obstet Gynecol 2006; 107: 896-900.
37. Darmochwal-Kolarz D, Kolarz B, Surdacka A, et al. The expression and concentration of CD40 ligand in normal pregnancy and pre-eclampsia. J Reprod Imunol 2009; 79: 215-219.
38. Mellembakken JR, Solum NO, Ueland T, et al. Increased concentrations of soluble CD40 ligand, RANTES and GRO-alpha in preeclampsia - possible role of platelet activation. Thromb Haemost 2001; 86: 1272-1276.
39. Mason PJ, Chakrabarti S, Albers AA, et al. Plasma, serum, and platelet expression of CD40 ligand in adults with cardiovascular disease. Am J Cardiol 2005; 96: 1365-1369.
40. Weber M, Rabenau B, Stanisch M, et al. Influence of sample type and storage conditions on soluble CD40 ligand assessment. Clin Chem 2006; 52: 888-891.
41. van Kooten C. Immune regulation by CD40-CD40-l interactions - 2; Y2K update. Front Biosci 2000; 5: D880-693.
42. Howard LM, Miller SD. Immunotherapy targeting the CD40/CD154 costimulatory pathway for treatment of autoimmune disease. Autoimmunity 2004; 37: 411-418.
43. Danese S, Sans M, Fiocchi C. The CD40/CD40L costimulatory pathway in inflammatory bowel disease. Gut 2004; 53: 1035-1043.